Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution containing glucose monohydrate as the active ingredient. It is supplied in a sterile liquid form for parenteral administration, typically used in clinical settings for energy provision and fluid balance. The product is marketed in the European Union and requires a prescription. It is packaged in single‑use containers and is intended for use under the supervision of qualified health‑care professionals.

Glucose Viaflo Baxter is indicated for several clinical situations where rapid glucose delivery and fluid replacement are required.

- Treatment of hypoglycemia when oral intake is not feasible. - Component of parenteral nutrition regimens to supply carbohydrate calories. - Fluid and electrolyte replacement in patients unable to tolerate oral fluids. - Support of plasma osmolarity during intravenous therapy. - Adjunct in perioperative care to maintain blood glucose levels.

Intravenous glucose monohydrate can elicit a spectrum of effects that reflect its role as a rapid energy source and its influence on plasma osmolarity. Most reactions are mild and reversible, while rare events may require medical attention.

Common: - A temporary increase in blood glucose concentration that usually normalizes without intervention. - Mild gastrointestinal discomfort such as nausea or occasional vomiting shortly after infusion. - Localized irritation or erythema at the catheter insertion site.

Serious: - Marked hyperglycemia that can progress to osmotic diuresis and dehydration. - Fluid overload manifesting as pulmonary edema, especially in patients with compromised cardiac function. - Immediate hypersensitivity reactions, including rash, bronchospasm, or anaphylactic shock.

When using Glucose Viaflo Baxter, clinicians should observe several precautionary measures to minimize risks and ensure appropriate patient monitoring.

- Verify blood glucose level before administration to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Monitor electrolytes, particularly potassium and sodium, during and after infusion. - Use aseptic technique to reduce risk of catheter‑related infection. - Assess for signs of allergic reaction during the first minutes of infusion. - Consider alternative carbohydrate sources in patients with known glucose intolerance.

Glucose Viaflo Baxter may interact with other medications or clinical conditions, influencing its safety and efficacy.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic dextrose solutions, increasing risk of hyperosmolar complications. - Use in patients with uncontrolled diabetes mellitus when glucose levels are already elevated.

Use with caution: - Concurrent diuretics or potassium‑sparing agents that affect electrolyte balance. - Medications that prolong QT interval, as rapid glucose shifts may influence cardiac electrophysiology. - Renal replacement therapy, requiring adjustment of glucose infusion rates.